{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T05:24:54.928116+00:00","company":{"ticker":"USNA","cik":896264,"company_name":"USANA HEALTH SCIENCES INC"},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"d52176a2d87198a106a68859234149fa1ca93e3e","cik":896264,"ticker":"USNA","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":"$0.41","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$7.5 million","period_text":"first quarter ended April 4, 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":"$250 million"},"claim":"USANA HEALTH SCIENCES INC reported first quarter ended April 4, 2026 results: revenue $250 million, net income $7.5 million, EPS $0.41. Guidance reaffirmed.","evidence_excerpt":"(NYSE: USNA) today announced financial results for its fiscal first quarter ended April 4, 2026. Key Financial Results First Quarter 2026 vs. First Quarter 2025 • Net sales of $250 million versus $250 million. • Net earnings of $7.5 million versus $9.4 million. • Diluted EPS of $0.41 as compared with $0.49. • Adjusted diluted EPS (1) of $0.61 as compared with","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000896264-26-000030","anchor_url":"https://secwatch.observer/filing/0000896264-26-000030#claim-d52176a2d87198a106a68859234149fa1ca93e3e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/896264/000089626426000030/0000896264-26-000030-index.htm"},{"fact_type":"debt_financing","fact_key":"2dc78e1a5f295e5bf69dfa59b105ca0801e4d9f3","cik":896264,"ticker":"USNA","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2025-07-01T23:59:59+00:00","payload":{"counterparty":"Bank of America, N.A.","effective_date":"2025-06-27","event":"amendment","instrument_type":"revolving_credit","interest_rate_text":"Term SOFR plus the applicable margin","item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":"up to $75 million"},"claim":"USANA HEALTH SCIENCES INC amended revolving credit of up to $75 million with Bank of America, N.A. at Term SOFR plus the applicable margin.","evidence_excerpt":"Swingline Lender and Letter of Credit Issuer, and the other lenders party thereto. The Credit Agreement provides for a revolving credit limit for loans to the Company of up to $75 million (the “Credit Facility”). In addition, at the option of the Company, and subject to certain conditions, the Company may request to increase the aggregate commitment under the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000896264-25-000175","anchor_url":"https://secwatch.observer/filing/0000896264-25-000175#claim-2dc78e1a5f295e5bf69dfa59b105ca0801e4d9f3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/896264/000089626425000175/0000896264-25-000175-index.htm"},{"fact_type":"shareholder_vote","fact_key":"889c3e9a496597b46e52eb42283939e8dae6e03b","cik":896264,"ticker":"USNA","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2024-05-07T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-06","outcome":"passed","proposal_text":"Advisory approval of executive compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"543,092","subject":null,"votes_abstain":"3,249","votes_against":"414,043","votes_for":"16,559,671","votes_withheld":null}]},"claim":"USANA HEALTH SCIENCES INC shareholders approved Advisory approval of executive compensation at the 2024-05-06 meeting.","evidence_excerpt":"USANA shareholders voted to approve, on an advisory basis, executive compensation as set forth below: Number of Shares For Number of Shares Against Number of Shares Abstaining Broker Non-Votes 16,559,671 414,043 3,249 543,092","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000896264-24-000168","anchor_url":"https://secwatch.observer/filing/0000896264-24-000168#claim-889c3e9a496597b46e52eb42283939e8dae6e03b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/896264/000089626424000168/0000896264-24-000168-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7f74e4ef911e43fba53046d1789732d3632d0ef7","cik":896264,"ticker":"USNA","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2024-05-07T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-06","outcome":"passed","proposal_text":"Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2024","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"634","votes_against":"60,804","votes_for":"17,458,617","votes_withheld":null}]},"claim":"USANA HEALTH SCIENCES INC shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2024 at the 2024-05-06 meeting.","evidence_excerpt":"USANA shareholders voted to ratify the Board’s selection of KPMG LLP as our independent registered public accounting firm for fiscal year 2024 as set forth below: Number of Shares For Number of Shares Against Number of Shares Abstaining Broker Non-Votes 17,458,617 60,804 634 -","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000896264-24-000168","anchor_url":"https://secwatch.observer/filing/0000896264-24-000168#claim-7f74e4ef911e43fba53046d1789732d3632d0ef7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/896264/000089626424000168/0000896264-24-000168-index.htm"},{"fact_type":"shareholder_vote","fact_key":"30f34f5d5c1dacfbb8112f6c68d79f1489f13117","cik":896264,"ticker":"USNA","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2024-05-07T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-06","outcome":"passed","proposal_text":"Election of eight directors","proposal_type":"director_election","results":[{"broker_non_votes":"543,092","subject":"Kevin G. Guest","votes_abstain":"-","votes_against":null,"votes_for":"16,858,545","votes_withheld":"118,418"},{"broker_non_votes":"543,092","subject":"Xia Ding","votes_abstain":"-","votes_against":null,"votes_for":"16,639,033","votes_withheld":"337,930"},{"broker_non_votes":"543,092","subject":"John T. Fleming","votes_abstain":"-","votes_against":null,"votes_for":"16,620,330","votes_withheld":"356,633"},{"broker_non_votes":"543,092","subject":"Gilbert A. Fuller","votes_abstain":"-","votes_against":null,"votes_for":"15,908,052","votes_withheld":"1,068,911"},{"broker_non_votes":null,"subject":"J. Scott Nixon, CPA","votes_abstain":"543,092","votes_against":null,"votes_for":"16,615,187","votes_withheld":"361,776"},{"broker_non_votes":"543,092","subject":"Peggie J. Pelosi","votes_abstain":"-","votes_against":null,"votes_for":"16,623,358","votes_withheld":"353,605"},{"broker_non_votes":"543,092","subject":"Frederic Winssinger","votes_abstain":"-","votes_against":null,"votes_for":"16,552,853","votes_withheld":"424,110"},{"broker_non_votes":"543,092","subject":"Timothy E. Wood, Ph.D.","votes_abstain":"-","votes_against":null,"votes_for":"16,618,063","votes_withheld":"358,900"}]},"claim":"USANA HEALTH SCIENCES INC shareholders approved Election of eight directors at the 2024-05-06 meeting.","evidence_excerpt":"USANA shareholders voted to elect eight individuals to the Board of Directors for the succeeding year as set forth below: Name Number of Shares For Number of Shares Withheld Number of Shares Abstaining Broker Non-Votes Kevin G. Guest 16,858,545 118,418 - 543,092 Xia Ding 16,639,033 337,930 - 543,092 John T. Fleming 16,620,330 356,633 - 543,092 Gilbert A. Fuller 15,908,052 1,068,911 - 543,092 J. Scott Nixon, CPA 16,615,187 361,776 543,092 Peggie J. Pelosi 16,623,358 353,605 - 543,092 Frederic Winssinger 16,552,853 424,110 - 543,092 Timothy E. Wood, Ph.D. 16,618,063 358,900 - 543,092","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000896264-24-000168","anchor_url":"https://secwatch.observer/filing/0000896264-24-000168#claim-30f34f5d5c1dacfbb8112f6c68d79f1489f13117","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/896264/000089626424000168/0000896264-24-000168-index.htm"},{"fact_type":"earnings_release","fact_key":"e4b6fb843b8c6520eb63b957722687ebf0ecf688","cik":896264,"ticker":"USNA","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2024-04-30T23:59:59+00:00","payload":{"eps_text":"$0.86","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 30, 2024","report_date":"2024-04-30","result_type":"reported_results","revenue_text":"$228 million"},"claim":"USANA HEALTH SCIENCES INC reported first quarter ended March 30, 2024 results: revenue $228 million, EPS $0.86. Guidance reaffirmed.","evidence_excerpt":"Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended March 30, 2024. Key Financial & Operating Results • First quarter net sales were $228 million versus $248 million during Q1 2023, and increased 2% sequentially in constant currency. • First quarter diluted EPS was $0.86 as compared with $0.95 during Q1 2023. • Company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000896264-24-000138","anchor_url":"https://secwatch.observer/filing/0000896264-24-000138#claim-e4b6fb843b8c6520eb63b957722687ebf0ecf688","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/896264/000089626424000138/0000896264-24-000138-index.htm"}]}